Omnicell, INC

Omnicell, Inc. announced solid second quarter 2026 financial results, with revenues at the high end of expectations and increased full-year guidance for non-GAAP EBITDA and EPS.

Omnicell, Inc. announced the appointment of Nnamdi Njoku as President, effective July 1, 2026, while he retains his COO role, as Randall Lipps continues as CEO and Chairman.

Omnicell, Inc. held its 2026 Annual Meeting of Stockholders, approving amendments to its equity incentive plan and certificate of incorporation, and electing new directors.

Omnicell, Inc. announced robust first-quarter 2026 financial results, driven by strong demand for its connected devices and core solutions, leading to an increase in full-year non-GAAP EBITDA and EPS guidance.

Omnicell announced solid fourth quarter and full year 2025 financial results, exceeding guidance mid-points for key metrics and launching its next-generation dispensing system, Titan XT.

Omnicell, Inc. announced the launch of Omnicell Titan XT, its next-generation automated dispensing system designed to empower autonomous medication management, powered by its OmniSphere cloud platform.

Omnicell, Inc. announced its first-quarter 2026 financial results, showcasing a 15% increase in total revenues to $309.9 million, driven by robust product and service revenue growth.

Omnicell reports a 10% increase in Q3 2025 total revenues and a significant turnaround to net income for the nine-month period, driven by product and service growth, despite a quarterly net income decline.

Omnicell, Inc. reported increased revenues and net income for the second quarter of 2025, driven by growth in service offerings and favorable product costs, alongside strategic shifts in its executive team and share repurchase programs.

Omnicell's Q1 2025 revenue increased by 10% year-over-year, driven by product and service revenue growth, while the company navigates potential impacts from global trade tariffs.

Omnicell's Q3 2024 results show a decrease in product revenue offset by growth in service revenue, resulting in a net loss for the nine-month period.

Omnicell's Q2 2024 results show a decrease in product revenue, offset by growth in service revenue, alongside cost-cutting measures and restructuring activities.

Omnicell reports a 7% increase in total revenues for 2025, driven by service growth and strategic investments in autonomous medication management, despite a significant drop in net income and reduced product bookings.

Omnicell's 2024 10-K filing reveals a company navigating market headwinds while strategically investing in long-term growth through automation and recurring revenue streams.

Omnicell's 2023 annual report provides a list of subsidiaries and details the company's focus on medication management solutions and the vision of the Autonomous Pharmacy.

Randall A Lipps, CHAIRMAN, CEO and a Director of Omnicell, Inc., sold 10,000 shares of common stock on July 15, 2026 for $47.00 per share.

Eileen J. Voynick, a Director at Omnicell, Inc., was granted 4,785 restricted shares under the company's equity incentive plan.

Omnicell, Inc. reports a stock grant to Director Robin Gene Seim, with shares vesting one year from the grant date.

Omnicell, Inc. Director Bruce E. Scott was granted restricted stock under the company's equity incentive plan.

Omnicell, Inc. Director Edward Peter Bousa acquired 4,603 shares of common stock through a restricted stock grant.

Omnicell, Inc. reports a stock grant to Director Joanne B. Bauer, with shares vesting in one year.

Omnicell, Inc. has announced its 2026 Annual Meeting of Stockholders, to be held virtually on May 19, 2026, with key proposals including director elections and equity plan amendments.

Omnicell is holding its annual meeting to elect directors, approve executive compensation, amend its equity incentive plan, and ratify its accounting firm.

Omnicell's upcoming annual meeting includes proposals for director elections, executive compensation approval, an equity incentive plan amendment, and auditor ratification.

Wellington Management Group LLP and its affiliates have reported beneficial ownership of 5.96% of Omnicell, Inc. common stock as of March 31, 2026.

Vanguard Capital Management has reported beneficial ownership of 5% of Omnicell Inc.'s common stock as of March 31, 2026.

Vanguard Portfolio Management has reported a beneficial ownership of 7.13% in Omnicell Inc. common stock as of March 31, 2026.

Millennium Management LLC, along with Millennium Group Management LLC and Israel A. Englander, reported a 5.0% beneficial ownership stake in Omnicell, Inc. common stock.

The Vanguard Group has reported a 0% beneficial ownership in Omnicell Inc. common stock following an internal corporate realignment.

Dimensional Fund Advisors LP has reported a passive 5.1% beneficial ownership stake in Omnicell Inc. common stock.